IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Spirit Airlines Reverses Pilot Furlough Plans Amid Updated Staffing Outlook 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Waymo Issues Recall After Reports of Self-Driving Cars Illegally Passing School Buses in Texas 
Visa to Move European Headquarters to London’s Canary Wharf 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis (SIX:NOVN), generating 2.6 billion Swiss francs ($2.90 billion).
The sale, conducted through an accelerated bookbuilding process, saw Emasan AG offload 26.5 million Novartis shares at 98.25 Swiss francs each. Goldman Sachs, acting as the bookrunner, confirmed the transaction on Wednesday.
This move marks a substantial capital realization for Emasan AG, highlighting a strategic shift in the investment portfolio of the Sandoz family. Novartis, a global leader in pharmaceuticals, has been a key holding for Emasan AG, making this divestment particularly notable for investors tracking the Swiss stock market.
The deal is expected to impact Novartis’s share performance, given the scale of the transaction. Market analysts are closely watching how this sell-off influences investor sentiment and Novartis’s future stock valuation.
This article was generated with AI assistance and reviewed by an editor.
